Elevated amylase in plasma represents an adverse prognostic marker in patients with metastatic pancreatic cancer

Abstract

Background and aim: Clinical outcome of metastatic pancreatic cancer (PC) patients is dismal and novel prognostic factors might help to stratify patients into different risk groups in clinical trials and clinical decision-making. Lipase and Amylase are recommended markers for diagnosis of acute pancreatitis, but their significance with regard to prognostic relevance in metastatic PC is uncertain. The aim of this study was to investigate the prognostic relevance of these two parameters concerning survival of patients suffering from metastatic PC. Method: This large retrospective study includes 351 patients with metastatic PC, who were treated between the years 2004 and 2015 in a single academic institution. Cancer-specific survival (CSS) was analysed using the Kaplan-Meier method. To further evaluate the prognostic significance of lipase and amylase, univariate and multivariate values were calculated using Cox proportional models. Results: In our study cohort, amylase and lipase values were highly correlated (R=0.821, p

Datum der Bewilligung	2019
Originalsprache	Englisch
Gradverleihende Hochschule	Medizinische Universität Graz
Betreuer/-in	Michael Stotz (Betreuer*in) & Martin Pichler (Mitbetreuer*in)